Global pharmaceutical leader Lupin Limited announced the commercial launch of Dasatinib Tablets in the United States after FDA approval. Consequently, this launch expands Lupin’s oncology portfolio and delivers high-quality generic therapies directly to American patients in partnership with Pharmascience Inc.
The newly introduced Dasatinib Tablets come in 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg strengths, allowing physicians to tailor dosage effectively. Furthermore, these tablets match the reference drug Sprycel® in safety, efficacy, and quality. This is offering U.S. patients a trusted alternative at more affordable prices.
Clinically, Dasatinib Tablets treat several serious blood cancers. For example, the drug targets adults newly diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. In addition, it addresses adults with chronic, accelerated, or blast phase Ph+ CML resistant to prior treatments like imatinib. Moreover, it treats adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who have failed previous therapies.
Beyond adult care, Lupin provides Dasatinib Tablets for pediatric patients. Specifically, children one year or older with Ph+ CML in chronic phase, or newly diagnosed Ph+ ALL, can use the tablets alongside chemotherapy. Consequently, Lupin emphasizes access for patients of all ages, demonstrating its commitment to comprehensive oncology care.
The launch arrives amid strong U.S. demand for Dasatinib. For instance, industry reports show Sprycel® recorded estimated annual sales of around USD 930 million through October 2025. Therefore, this underscores the commercial opportunity for generic alternatives that improve patient access while maintaining treatment standards.
Analysts anticipate that generic Dasatinib Tablets could reduce treatment costs and enhance affordability for patients and healthcare providers. Moreover, with rising demand for accessible cancer therapies, generics play a key role in broadening coverage without sacrificing quality. Nevertheless, adoption depends on physicians and insurance reimbursement decisions in the competitive U.S. market.
Lupin's ability to develop and launch Dasatinib will help strengthen its market presence in the areas of complex generics and oncology. Along with the development of a diverse portfolio of prescription products (branded, generic, complex therapy, and active pharmaceutical ingredients). Lupin has R&D capabilities in 15 world-class manufacturing operations and 7 R&D centres around the globe. This enables Lupin to distribute its products in more than 100 markets, including the U.S. and India.
Lupin’s Chief Executive highlighted the company’s mission to improve patient outcomes through affordable medications. Furthermore, he noted that the partnership with Pharmascience Inc., a leading Canadian pharmaceutical manufacturer. That enabled efficient production and high-quality Dasatinib Tablets delivery.
The launch continues Lupin’s pattern of expanding U.S. generics offerings. For example, the company has introduced multiple products across therapeutic areas, including cardiovascular and chronic disease treatments. That reinforces its competitive presence in the American market.
The introduction of Dasatinib Tablets as a generic has been well received by healthcare stakeholders (e.g., oncologists and patient advocacy groups). Thus, there is hope that the increased competition associated with the introduction of other generics in oncological conditions will decrease the price. Thereby allowes patients to remain on a long-term treatment programme without financial hardship.
The success that Lupin has achieved in launching Dasatinib Tablets may serve as a model for the introduction of further oncology generics. Additionally, treatment options will become more available to patients and their providers throughout the U.S. Because Dasatinib Tablets will be available through specialty pharmacies and oncology clinics.
Overall, Lupin’s introduction of Dasatinib Tablets in the U.S. marks a major expansion of its portfolio. Therefore, this move promises to improve patient care, increase competition, and broaden access to essential cancer therapies across the country.
